Baricitinib triggering a central nervous system inflammatory-demyelinating disease: A case report

Multiple Sclerosis Journal - Experimental, Translational and Clinical · Published 2026-01-01 · DOI 10.1177/20552173251409943

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1177/20552173251409943

Abstract

Janus kinase inhibitors (JAKis), such as baricitinib, target the Janus kinase/signal transducers and activators of transcription pathway to regulate proinflammatory cytokines and T-helper cell activity, thereby reducing inflammation. Despite their therapeutic benefits, inflammatory demyelinating diseases of the central nervous system (CNS) have been reported in association with JAKi treatment, most previously involving tofacitinib in patients with rheumatoid arthritis. We report the first case of a CNS inflammatory demyelinating disease that was possibly exacerbated by baricitinib, underscoring the need for heightened clinical vigilance and close monitoring of patients receiving JAKi therapy.

Abstract from DOAJ. Public domain (CC0 1.0).

Read the article at the publisher →

Publication details

Year
2026

Related articles